Compare · DRTS vs SYK
DRTS vs SYK
Side-by-side comparison of Alpha Tau Medical Ltd. (DRTS) and Stryker Corporation (SYK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DRTS and SYK operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- SYK is the larger of the two at $122.63B, about 102.8x DRTS ($1.19B).
- Over the past year, DRTS is up 349.8% and SYK is down 17.8% - DRTS leads by 367.6 points.
- DRTS has been more active in the news (12 items in the past 4 weeks vs 5 for SYK).
- SYK has more recent analyst coverage (25 ratings vs 7 for DRTS).
- Company
- Alpha Tau Medical Ltd.
- Stryker Corporation
- Price
- $13.54+13.78%
- $319.74-3.44%
- Market cap
- $1.19B
- $122.63B
- 1M return
- +44.66%
- +2.90%
- 1Y return
- +349.83%
- -17.79%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 12
- 5
- Recent ratings
- 7
- 25
Alpha Tau Medical Ltd.
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.
Stryker Corporation
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Latest DRTS
- SEC Form 6-K filed by Alpha Tau Medical Ltd.
- Alpha Tau Successfully Treats First Immunocompromised Patient with Recurrent Cutaneous Squamous Cell Carcinoma in its ADMIRE Study at Banner MD Anderson Cancer Center
- Chief Financial Officer Levy Raphi sold $31,782 worth of Ordinary Shares (2,270 units at $14.00) and exercised 2,270 units of Ordinary Shares at a strike of $2.98 (SEC Form 4)
- Chief Financial Officer Levy Raphi exercised 17,873 units of Ordinary Shares at a strike of $2.98 and sold $232,397 worth of Ordinary Shares (17,873 units at $13.00) (SEC Form 4)
- Chief Financial Officer Levy Raphi exercised 2,127 units of Ordinary Shares at a strike of $2.98 and sold $27,691 worth of Ordinary Shares (2,127 units at $13.02) (SEC Form 4)
- Chief Financial Officer Levy Raphi sold $240,044 worth of Ordinary Shares (20,000 units at $12.00), decreasing direct ownership by 18% to 90,180 units (SEC Form 4)
- Chief Financial Officer Levy Raphi sold $220,004 worth of Ordinary Shares (20,000 units at $11.00), decreasing direct ownership by 15% to 110,180 units (SEC Form 4)
- SEC Form 6-K filed by Alpha Tau Medical Ltd.
- Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet
- Chief Financial Officer Levy Raphi sold $167,051 worth of Ordinary Shares (17,500 units at $9.55), decreasing direct ownership by 12% to 130,180 units (SEC Form 4)
Latest SYK
- Stryker expands Mako robotics portfolio with full market release of Mako RPS
- BMO Capital Markets initiated coverage on Stryker with a new price target
- Stryker to announce second quarter 2026 financial results
- Stryker Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Stryker partners with professional golfer Shane Lowry to spotlight the caregiver journey in joint replacement
- Fresh Off Its Nasdaq Debut, a Regenerative-Medicine Upstart Is Stacking Its Board With Big-Pharma Firepower
- President and COO Stiles Spencer S gifted 1,607 shares, decreasing direct ownership by 2% to 76,027 units (SEC Form 4)
- Stryker launches TPX HD® power tool, supporting demanding orthopaedic procedures
- VP, Chief Legal Officer Fletcher Robert S sold $1,394,409 worth of shares (4,544 units at $306.87) as part of a pre-agreed trading plan, decreasing direct ownership by 30% to 10,582 units (SEC Form 4)
- Director Stryker Ronda E sold $96,792,669 worth of shares (310,000 units at $312.23) (SEC Form 4)